Diligence memo · auto-generated · as of July 2, 2026
Spry Therapeutics Inc.
Spry Therapeutics Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Spry Therapeutics Inc. operates in Pharma, based in MUMBAI, MAHARASHTRA.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Spry Therapeutics Inc. has raised $15M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $15M on 2024-10-03.
Most recent recorded round closed around 2024-10-03.
Valuation (modeled)modeled
Provath models Spry Therapeutics Inc. at approximately $69M (range $17M–$140M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.01× the median modeled value of Series A Pharma companies in 2022–2024 (24 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 21 mo ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 73% of Pharma peers (310 compared).
Modeled value ranks above 60% of those peers.
Closest niche peers: Carmine Therapeutics, Inc., Triomics, Inc., Spiral Therapeutics Inc, Convelo Therapeutics, Inc., ADvantage Therapeutics, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.